NCT01692470View on ClinicalTrials.gov

A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection

WithdrawnOBSERVATIONAL

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Interventions

DRUG

No intervention

Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.